In this issue:
Stapokibart for moderate-to-severe AD
Rituximab for moderate-to-severe pemphigus vulgaris/pemphigus foliaceus
Cutaneous malignancy after biologic therapy for inflammatory disease
Dupilumab and risk of maternal adverse pregnancy outcomes
Dupilumab in super-elderly patients with bullous pemphigoid
Current treatments and future directions for HS
Bimekizumab impact on patient-reported outcomes in HS
Lebrikizumab biomarkers in moderate-to-severe AD
Dupilumab for AD and risk of otitis media
Rituximab for treatment-refractory mucous membrane pemphigoid
Please login below to download this issue (PDF)